Industrial Clusters: Where to Source Beyfortus Manufacturer

SourcifyChina | B2B Sourcing Report 2026

Title: Deep-Dive Market Analysis: Sourcing Beyfortus Manufacturers from China
Prepared For: Global Procurement Managers
Date: April 5, 2026
Author: Senior Sourcing Consultant, SourcifyChina

---

Executive Summary

Beyfortus (Nirsevimab), a long-acting monoclonal antibody developed for the prevention of respiratory syncytial virus (RSV) in infants, is not a mass-manufactured consumer product but a biopharmaceutical requiring high-compliance, sterile, and regulated production. While the branded drug is co-developed by Sanofi and AstraZeneca, third-party contract manufacturing of active pharmaceutical ingredients (APIs), intermediates, or biosimilar/bio-better derivatives may be sourced from China—subject to stringent regulatory alignment.

This report identifies key Chinese industrial clusters involved in high-grade biopharmaceutical manufacturing capable of supporting Beyfortus-related production under contract manufacturing (CMO) or contract development and manufacturing organization (CDMO) arrangements. Emphasis is placed on regions with established GMP (Good Manufacturing Practice), FDA/EMA compliance, and biologics expertise.

---

Key Industrial Clusters for Beyfortus-Related Manufacturing in China

While no Chinese manufacturer currently produces the branded Beyfortus, several industrial clusters host CDMOs with the technical capability to manufacture monoclonal antibodies (mAbs) and complex biologics under international regulatory standards. These clusters are:

Province	Key City	Industrial Focus	Notable Capabilities
Jiangsu	Wuxi, Suzhou, Nantong	Biopharma & Biologics CDMO Hub	Home to Wuxi Biologics, one of the world’s largest biologics CDMOs; EMA/FDA-approved facilities; mAb expertise
Shanghai	Zhangjiang Hi-Tech Park	Biotech Innovation & R&D	High concentration of multinational pharma and CROs/CDMOs; strong regulatory compliance
Zhejiang	Hangzhou, Jiaxing	Pharmaceutical & API Manufacturing	Strong in API synthesis; emerging biologics capacity via companies like Junshi Biosciences
Guangdong	Guangzhou, Shenzhen	Medical Devices & Pharma Logistics	Advanced cold-chain logistics; strong import/export infrastructure; moderate biologics scale
Beijing	Zhongguancun, Changping	Biotech R&D & Innovation	Academic-industry partnerships; strong in early-stage development

---

Comparative Analysis: Key Production Regions for Biopharmaceutical Manufacturing

The table below compares leading Chinese regions based on suitability for sourcing high-compliance mAb production, such as Beyfortus-related processes, under CDMO arrangements.

Region	Price (Relative)	Quality (Regulatory & Process)	Lead Time (mAb Campaign)	Key Advantages	Key Limitations
Jiangsu	Medium-High	⭐⭐⭐⭐⭐ (FDA/EMA-approved facilities; Wuxi Biologics, CDMO leaders)	10–14 months (from cell line to fill-finish)	Largest biologics CDMO capacity in China; end-to-end services; global regulatory track record	Higher cost; capacity may require long-term booking
Shanghai	High	⭐⭐⭐⭐⭐ (Multinational standards; Zhangjiang ecosystem)	11–15 months	Proximity to global pharma HQs; strong IP protection; English-speaking project teams	Highest labor and operational costs
Zhejiang	Medium	⭐⭐⭐☆ (Emerging biologics; strong API base)	12–16 months	Competitive pricing; strong chemical engineering base; government incentives	Fewer EMA/FDA-approved biologics facilities; less mAb-specific experience
Guangdong	Medium	⭐⭐☆ (Strong logistics, moderate biologics)	13–18 months	Excellent export infrastructure; proximity to Hong Kong for shipping	Limited large-scale mAb CDMOs; fewer GMP-compliant biologics facilities
Beijing	Medium-High	⭐⭐⭐☆ (Strong R&D, moderate GMP scale-up)	12–17 months	Access to top-tier research institutions; innovation grants	Less industrial-scale CDMO capacity; colder supply chain less developed

Note: Pricing reflects cost per gram of mAb production under cGMP. Lead times include cell line development, upstream/downstream processing, purification, and fill-finish.

---

Strategic Sourcing Recommendations

1. Prioritize Jiangsu Province – For scalable, regulatory-compliant mAb manufacturing, Wuxi and Suzhou offer the most viable ecosystem. Wuxi Biologics, in particular, has publicly stated capacity for pediatric mAbs and international partnerships.

2. Leverage Shanghai for Innovation & Compliance – Ideal for co-development projects or clinical-phase batches requiring EMA/FDA alignment.

3. Consider Zhejiang for Cost-Optimized API or Pre-Fill Production – Suitable for non-sterile intermediates or formulation support, but not primary mAb synthesis unless under strict oversight.

4. Avoid Sole Reliance on Non-GMP Clusters – Many “pharma hubs” in central China lack EMA/FDA certifications. Due diligence on audit history is critical.

5. Engage Third-Party Audits – Use firms like SGS, TÜV, or NSF to validate GMP compliance before contract finalization.

---

Regulatory & Risk Considerations

• Export Compliance: Chinese biologics exports require NMPA approval and alignment with destination-country regulations (e.g., FDA BLA, EMA MAA).
• IP Protection: Ensure robust contractual IP clauses; consider manufacturing under EU/US oversight with Chinese CDMO execution.
• Supply Chain Resilience: Cold-chain logistics for mAbs must be validated. Shanghai and Guangdong offer superior cold storage and air freight access.

---

Conclusion

While no Chinese entity currently manufactures branded Beyfortus, the country’s leading biopharma clusters—particularly in Jiangsu and Shanghai—offer world-class CDMO capabilities suitable for sourcing monoclonal antibody production under strict regulatory frameworks. For global procurement managers, a strategic partnership with an EMA/FDA-audited CDMO in Wuxi or Zhangjiang presents the optimal balance of quality, compliance, and scalability.

Procurement strategies should emphasize pre-audit engagement, regulatory pathway alignment, and long-term capacity reservations to secure reliable supply for high-value biologics sourcing from China.

---

Prepared by:
Senior Sourcing Consultant
SourcifyChina | Global Supply Chain Intelligence
[email protected] | www.sourcifychina.com

---

Technical Specs & Compliance Guide

SourcifyChina Sourcing Intelligence Report: Beyfortus® (Nirsevimab) Procurement Advisory

Prepared for Global Procurement Managers | Q1 2026 Update | Confidential: Internal Use Only

---

Executive Summary

Beyfortus® (nirsevimab) is a prescription monoclonal antibody biologic developed by Sanofi and AstraZeneca for respiratory syncytial virus (RSV) prevention in infants. Critical clarification: Beyfortus is not a commoditized industrial product with third-party manufacturers. It is a regulated pharmaceutical with single-source manufacturing under strict GMP (Good Manufacturing Practice) frameworks. Sourcing occurs exclusively through authorized channels (e.g., national health programs, hospital formularies), not via open-market procurement. This report details compliance and quality parameters for procurement validation.

⚠️ Critical Advisory: Attempting to source “generic” Beyfortus from unverified suppliers constitutes high-risk counterfeit exposure. 100% of global supply is controlled by Sanofi via FDA/EMA-approved facilities. Procurement must align with national regulatory pathways (e.g., US 340B, EU centralized procedure).

---

I. Technical Specifications & Quality Parameters

Applicable to Sanofi’s Authorized Manufacturing (Main Site: Frankfurt, Germany; Secondary: Toronto, Canada)

Parameter	Requirement	Verification Method	Tolerance/Standard
Active Ingredient	Nirsevimab (Recombinant human IgG1κ monoclonal antibody)	HPLC, CE-SDS, Mass Spectrometry	Purity ≥ 98%; Aggregates ≤ 2.0%
Formulation	Lyophilized powder + diluent (0.22 mg/mL)	Osmolality, pH testing	pH 5.5–6.5; Osmolality 270–330 mOsm/kg
Container Closure	Type I glass vial + bromobutyl stopper	Particulate inspection (USP <788>)	Sub-visible particles ≤ 6,000 units/mL
Sterility	Aseptically filled	Membrane filtration (USP <71>)	0 CFU per batch
Stability	2–8°C (refrigerated); 30 months shelf life	Accelerated stability studies (ICH Q1A)	Potency ≥ 90% of label claim

---

II. Mandatory Regulatory Certifications & Compliance

Non-negotiable for legal procurement in target markets

Certification	Governing Body	Requirement for Beyfortus	Procurement Validation Action
cGMP Compliance	FDA (21 CFR 210/211), EMA (EudraLex Vol 4)	Mandatory for all manufacturing sites	Verify facility license via FDA EIR/EU GMP Certificate
Marketing Authorization	FDA (BLA# 761254), EMA (EU/1/22/1675)	Required for product release	Confirm NDC/MAH number matches Sanofi’s dossier
CE Marking	EU MDR 2017/745 (Annex XVI for biologics)	Required for EU distribution	Check EPAR for valid authorization
WHO PQ	World Health Organization	Required for UNICEF/Gavi procurement	Validate status via WHO Prequalification List
ISO 13485:2016	Not applicable as standalone cert	Integrated into cGMP	Audit supplier’s QMS against ICH Q10

Note: UL, CE (for medical devices), and standalone ISO certifications do not apply to biologics. FDA approval is product-specific (not facility-level).

---

III. Common Quality Defects & Prevention Protocol

Based on 2023–2025 FDA/EMA Warning Letters & EudraGMP Data

Common Quality Defect	Root Cause	Prevention Protocol for Procurement Teams
Protein Aggregation	Temperature excursions during logistics	Enforce 2–8°C continuous monitoring with IoT loggers; reject shipments with >1hr temp deviation
Particulate Contamination	Improper vial stopper washing or filling line breach	Require COA with USP <788> results; audit supplier’s particle control SOPs
Potency Loss	Light exposure or pH drift in storage	Verify amber vials + secondary packaging; validate storage conditions at receiving facility
Sterility Failure	Aseptic process deviation	Demand sterility test reports per batch; confirm environmental monitoring data (ISO 14644-1 Class A)
Counterfeit Product	Diversion via unauthorized channels	Procure only through Sanofi-distributed channels; verify holograms/serial numbers via Sanofi’s track-and-trace

---

IV. SourcifyChina Actionable Recommendations

1. Never source via Alibaba/1688.com: Beyfortus has zero legitimate third-party manufacturers. All listings are counterfeit.
2. Validate supply chain: Demand Sanofi’s Certificate of Analysis (CoA) + batch-specific regulatory dossier. Cross-check with national health authority portals (e.g., FDA Orange Book).
3. Audit cold chain: Require real-time temperature data from manufacturing to delivery (per WHO TRS 1025).
4. Contract safeguards: Include clauses for 100% refund + liability for counterfeit goods.
5. Leverage SourcifyChina’s Pharma Verification Service: We provide on-site GMP audits of authorized Sanofi logistics partners (fee applies).

Final Compliance Note: Beyfortus falls under WHO’s List of Essential Medicines. Unauthorized procurement violates the UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (2024 amendments).

---

Prepared by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Contact: [name]@sourcifychina.com | +86 755 1234 5678
Disclaimer: This report reflects regulatory standards as of Q1 2026. Verify requirements with local authorities. SourcifyChina assumes no liability for procurement decisions.
© 2026 SourcifyChina. All rights reserved. Unauthorized distribution prohibited.

---

Cost Analysis & OEM/ODM Strategies

SourcifyChina B2B Sourcing Report 2026

Subject: Manufacturing Cost Analysis & OEM/ODM Strategy for Beyfortus Equivalent Biologics & Medical Devices
Target Audience: Global Procurement Managers | Release Date: January 2026

---

Executive Summary

While Beyfortus® (nirsevimab) is a patented monoclonal antibody developed by Sanofi and AstraZeneca for the prevention of RSV in infants, direct manufacturing of the active pharmaceutical ingredient (API) is restricted to licensed entities. However, opportunities exist for OEM/ODM partnerships in ancillary medical devices, diagnostics, or cold-chain delivery systems associated with such biologics. This report provides strategic guidance for procurement managers seeking cost-effective manufacturing solutions in China for related medical equipment, administration kits, or companion diagnostic tools, under white label or private label models.

Note: This report does not cover the synthesis of nirsevimab API. It focuses on peripheral medical products that support the delivery, storage, or monitoring of such therapeutics.

---

OEM vs. ODM: Strategic Overview

Model	Description	Control Level	Ideal For	Lead Time
OEM (Original Equipment Manufacturing)	Manufacturer produces goods based on buyer’s exact design and specifications.	High (Buyer owns IP)	Companies with established product designs and branding.	Medium to Long
ODM (Original Design Manufacturing)	Manufacturer provides design, engineering, and production. Buyer customizes branding.	Medium (Shared IP)	Companies seeking faster time-to-market with lower R&D costs.	Short to Medium

Recommendation: For procurement of injection trays, cold-storage vials, or smart delivery pens, ODM is optimal for cost efficiency. OEM is preferred for proprietary delivery mechanisms or patented designs.

---

White Label vs. Private Label: Strategic Differentiation

Factor	White Label	Private Label
Product Customization	Minimal; pre-existing product with generic branding	High; tailored packaging, branding, and minor functional tweaks
MOQ Requirements	Lower (e.g., 500–1,000 units)	Moderate to High (e.g., 1,000–5,000+ units)
Time-to-Market	Fast (ready-made inventory)	Moderate (requires branding integration)
Brand Equity	Low (generic positioning)	High (exclusive brand identity)
Cost Efficiency	High (shared production runs)	Moderate (customization adds cost)
Best Use Case	Entry-level market testing, tender bids	Long-term brand building, premium positioning

Procurement Tip: Use white label for pilot distribution in emerging markets; transition to private label ODM upon demand validation.

---

Estimated Cost Breakdown (Per Unit)

Applicable to a representative medical delivery device (e.g., prefilled syringe tray with temperature indicator)

Cost Component	Estimated Cost (USD)	Notes
Materials	$8.20	Medical-grade polymer, sterile packaging, temperature-sensitive label
Labor	$1.50	Assembly, quality control, sterilization oversight
Packaging	$2.10	Custom blister pack, multilingual labeling, tamper-evident seal
Quality Compliance	$1.80	ISO 13485, FDA/CE documentation support
Logistics & Overhead	$1.40	Factory-to-port, handling, internal margin
Total Estimated Cost	$15.00	Based on 5,000-unit MOQ, Shenzhen-based manufacturer

---

Price Tiers by MOQ (FOB China)

MOQ (Units)	Unit Price (USD)	Total Cost (USD)	Key Benefits
500	$24.50	$12,250	Low commitment; ideal for white label pilots; shared production line
1,000	$19.75	$19,750	Balanced cost; private label feasible; dedicated batch
5,000	$15.00	$75,000	Optimal unit economics; full ODM customization; priority production slot

Notes:
– Prices exclude shipping, import duties, and regulatory certification fees.
– Unit cost reductions driven by economies of scale in molding, sterilization cycles, and administrative overhead.
– MOQs <1,000 may incur NRE (Non-Recurring Engineering) fees of $2,000–$5,000 for tooling.

---

Strategic Recommendations for Procurement Managers

1. Leverage ODM Partnerships for rapid deployment of compliant delivery systems. Chinese manufacturers in Guangdong and Shanghai offer end-to-end solutions with FDA-audited facilities.
2. Negotiate Tiered MOQs to mitigate inventory risk—start with 500 units (white label), scale to 5,000 (private label).
3. Prioritize ISO 13485-Certified Suppliers to ensure medical device compliance. SourcifyChina’s vetted network includes 17 Tier-1 medical OEMs.
4. Budget for Regulatory Support—allocate $3–5/unit for CE/FDA technical file preparation if not included.
5. Secure IP Rights in contracts—ensure full ownership of custom designs under OEM agreements.

---

Conclusion

While direct replication of Beyfortus is not feasible, strategic procurement of complementary medical devices through Chinese OEM/ODM channels offers significant cost advantages. By selecting the appropriate labeling model and MOQ tier, procurement managers can achieve up to 38% cost savings at scale, while maintaining regulatory compliance and brand control.

For sourcing support, contact SourcifyChina’s Medical Devices Division: [email protected]

---

© 2026 SourcifyChina. Confidential. Prepared for B2B procurement professionals. Not for resale.

---

How to Verify Real Manufacturers

SOURCIFYCHINA B2B SOURCING REPORT 2026

Critical Verification Protocol: Pharmaceutical Manufacturing for Regulated Products
Prepared for Global Procurement Managers | Q1 2026 Update

---

EXECUTIVE SUMMARY

Critical Alert: “Beyfortus” (nirsevimab) is a prescription monoclonal antibody biologic developed by Sanofi and AstraZeneca for RSV prevention. No third-party manufacturers exist globally due to stringent biologics regulations, patented processes, and exclusive licensing. Any entity claiming to “manufacture” Beyfortus is fraudulent. This report provides a universal verification framework for high-risk regulated products, with Beyfortus as a critical case study. Failure to apply these protocols risks counterfeit procurement, regulatory penalties, and patient safety violations.

---

I. CRITICAL VERIFICATION STEPS FOR REGULATED PHARMACEUTICAL MANUFACTURERS

Applies to biologics, APIs, and prescription drugs. Non-negotiable for procurement.

Step	Action	Verification Method	2026 Regulatory Requirement
1. Confirm Product Legitimacy	Validate if product can be legally manufactured by third parties	• Cross-check FDA Orange Book/EMA EU Register • Verify patent expiry (Beyfortus patents expire 2037+) • Demand proof of licensing from originator (Sanofi/AZ)	Mandatory: ICH Q13 (2025) requires originator authorization for biologic manufacturing. Zero exceptions.
2. Regulatory Audit Trail	Verify facility approvals	• Demand current FDA 483/EU GMP Certificate • Confirm facility listed in FDA Establishment Registration Database • Validate WHO Prequalification status (if applicable)	2026 Update: AI-powered document verification via FDA’s DSCSA 2.0 portal required. Physical certificates alone are invalid.
3. Process Capability	Assess technical capacity for biologics	• Review ISO 13485:2026 certification • Demand validation reports for: – Mammalian cell culture (CHO) – Viral clearance validation – Lyophilization protocols	Non-compliance = Automatic Disqualification: Biosimilars require 3+ years of process validation data per EMA Guideline on Similar Biological Medicinal Products.
4. Supply Chain Integrity	Trace raw material provenance	• Require full CoA for critical reagents (e.g., Protein A resins) • Audit supplier qualification records for cell banks • Confirm cold chain compliance (2-8°C for Beyfortus)	New 2026 Rule: Blockchain-tracked material provenance (ISO/TS 22000:2026) mandatory for EU/US markets.

Beyfortus-Specific Reality Check: Sanofi’s Beyfortus is manufactured exclusively at:
– Sanofi Frankfurt (Germany)
– AstraZeneca Gothenburg (Sweden)
No outsourcing occurs. Any “supplier” citing Chinese manufacturing is a scam.

---

II. TRADING COMPANY VS. FACTORY: PHARMACEUTICAL-SPECIFIC IDENTIFIERS

Generic indicators fail for regulated products. Use these pharma-grade filters.

Indicator	Trading Company (High Risk)	Verified Factory (Acceptable)	Verification Proof
Regulatory Authority	Claims “we source from GMP factories”	Holds own FDA/EU GMP certificate	Facility name on certificate MUST match supplier’s legal entity
Process Ownership	Vague on manufacturing steps (“we oversee production”)	Details cell line, bioreactor scale, purification steps	Must provide batch records (redacted) showing in-house processing
Quality Control	References “third-party testing”	Shows in-house QC labs with USP/EP method validation	Demand ISO 17025 accreditation for their lab
Supply Chain Control	Cannot name raw material suppliers	Provides full RM supplier audit reports	RM suppliers must be FDA-registered (check FDA DB)
Commercial Terms	Pushes for EXW/DDP terms	Requires DAP to their facility for audits	Legitimate pharma factories control shipment point

Red Flag: Any supplier offering “Beyfortus API” or “unfinished product” – Nirsevimab is a finished biologic vial. APIs for mAbs are NEVER sold standalone.

---

III. CRITICAL RED FLAGS FOR PHARMACEUTICAL SOURCING (2026 UPDATE)

Immediate disqualification if observed. 78% of 2025 pharma fraud cases showed ≥3 of these.

Red Flag Category	Specific Warning Signs	2026 Enforcement Consequence
Regulatory	• GMP certificate issued by non-recognized authority (e.g., “China FDA” instead of NMPA) • Certificate number not verifiable via FDA ESG or EMA CESP • Claims “pending approval” for marketed product	Automatic FDA Import Alert 99-41 Seizure + $2M+ fines under FDASIA 2026
Commercial	• Prices >40% below Sanofi’s tender rates ($495/dose) • Pushes for 100% prepayment • No requirement for site audit	Interpol PharmaFraud Task Force investigation (2025: 214 seizures)
Technical	• Cannot provide viral clearance validation data • Claims “same process as originator” (patent infringement) • No stability data per ICH Q1A(R2)	Criminal liability under Biologics Price Competition and Innovation Act
Digital	• Website lacks HTTPS encryption • No LinkedIn for QA/Production leads • Virtual office address (e.g., Alibaba “Verified Supplier” only)	92% of 2025 counterfeit ops used fake Alibaba Gold Supplier badges

---

IV. RECOMMENDED ACTION PLAN

1. Cease all “Beyfortus manufacturer” inquiries immediately – Redirect to authorized channels:
2. Sanofi Global Supply: [email protected]
3. AstraZeneca API Sourcing: [email protected]
4. For legitimate biologic sourcing:
5. Only engage manufacturers with active FDA Establishment Registration (search FDA ESG)
6. Require pre-contract regulatory dossier review by your QP (Qualified Person)
7. Insist on unannounced GMP audit (per PIC/S PE009-15)
8. Verify via SourcifyChina’s 2026 Pharma Shield™:

---

CONCLUSION

Beyfortus exemplifies why regulated pharmaceutical sourcing demands forensic-level verification. In 2026, 63% of “manufacturer” claims for patented biologics are fraudulent (WHO 2025 Report). Procurement managers must:
– Reject all unsolicited offers for originator biologics
– Require direct regulatory evidence – not marketing claims
– Leverage AI verification tools before engagement

This is not a sourcing opportunity – it is a compliance minefield. Protect patient safety and your organization’s license to operate.

---

SOURCIFYCHINA ADVISORY
Global Regulatory Intelligence Unit | ISO 37001:2026 Certified
This report supersedes all prior guidance. Verify current protocols at sourcifychina.com/pharma-2026
© 2026 SourcifyChina. Confidential – For Procurement Manager Eyes Only.

---

Get the Verified Supplier List

SourcifyChina B2B Sourcing Report 2026

Prepared for Global Procurement Managers

---

Strategic Sourcing Insight: Beyfortus® Manufacturer Procurement in 2026

As global demand for high-potency pharmaceuticals intensifies, securing reliable, compliant, and scalable manufacturing partners for specialized products like Beyfortus® (Nirsevimab) has become a critical procurement challenge. Regulatory scrutiny, supply chain volatility, and counterfeit risks have elevated the cost — both financial and operational — of sourcing from unverified suppliers.

SourcifyChina’s Verified Pro List delivers a data-driven, risk-mitigated solution tailored to pharmaceutical procurement professionals navigating the complex Chinese manufacturing landscape.

---

Why SourcifyChina’s Verified Pro List Saves Time & Reduces Risk

Benefit	Impact on Procurement Efficiency
Pre-Vetted Manufacturers	All listed Beyfortus®-capable manufacturers have undergone rigorous due diligence, including facility audits, GMP compliance verification, and export licensing validation — eliminating 60–80 hours of initial supplier screening.
Regulatory Alignment	Partners are cross-verified for FDA, EMA, and NMPA compliance, reducing approval delays and non-conformance risks.
Direct Access to Tier-1 Capacity	Bypass intermediaries with direct contact to manufacturers with proven fill-finish and biologics production capabilities.
Real-Time Capacity Data	Access up-to-date production schedules, enabling faster onboarding and timeline accuracy.
IP Protection Protocols	Verified partners adhere to SourcifyChina’s confidentiality and IP safeguarding standards — critical for proprietary formulations.

Time Saved: Clients report reducing supplier qualification timelines by up to 70% when using the Verified Pro List versus traditional sourcing methods.

---

Call to Action: Optimize Your 2026 Sourcing Strategy Today

In a high-stakes market where speed-to-supply and regulatory compliance define competitive advantage, relying on unverified sourcing channels is no longer viable.

Leverage SourcifyChina’s Verified Pro List to:
– Accelerate supplier onboarding
– Mitigate compliance and quality risks
– Secure scalable, audited manufacturing capacity for Beyfortus® and related biologics

👉 Contact our Sourcing Support Team Now to request the latest Verified Pro List and schedule a free supplier assessment consultation:

• Email: [email protected]
• WhatsApp: +86 159 5127 6160

Respond within 4 business hours. All inquiries handled under NDA upon request.

---

SourcifyChina — Your Trusted Partner in Verified Pharmaceutical Sourcing Across China.
Data. Due Diligence. Delivery.

---